Ambitious, knowledgeable & successful with a proven track record
John E. Milad
CEO & Founder
John is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. He had the belief and vision that the initial technology concept of a novel fluid management system could be transformed into a disruptive medical product addressing the unmet needs of the $73 billion global dialysis market by using innovation to empower patients and deliver better outcomes.
John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. He is currently an Advisory Board member of Digital Health Forum and is a regular speaker and panellist at global medtech and investment conferences. Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor. John has also held senior positions at Nitec Pharma AG (now Horizon Pharma plc), Atlas Venture and Nomura international and previously served as a member of the i4i selection panel at the NHS National Institute for Health Research. John has also served on the Board of Directors at Cellnovo Ltd, Symetis SA, BoneSupport AB and Advanced Cardiac Therapeutics Inc. He holds a BA in Political Science from The University of Chicago.
Chief Financial Officer
Willem has almost twenty years of investment banking, executive management, and private equity experience. Amongst his achievements, he was pivotal in the $1.6bn turnaround and public listing of FLAG Telecom and was co-founder and CFO of Arqaam Capital, one of the largest boutique investment banks based in Dubai. Previously, he has worked at the telecommunications firm Ameritech (SBC), as well the investment banks Deutsche Bank and Panmure Gordon. More recently, he led the acquisition and the subsequent merger of the real-estate agency Humberts with Chesterton. As Deputy Chairman of the enlarged Chesterton Humberts he oversaw its growth into one of the largest real-estate agencies in the UK.
Willem has undergraduate degrees in business administration and computer science from Lehigh University and an MBA from Kellogg Graduate School of Business.
Chief Commercial Officer
Peter has more than 25 years of experience in the medical device industry and started his professional career with Fresenius AG in Germany, later working at Fresenius Medical Care in Asia Pacific as regional Marketing Director for the dialysis products business. He moved on to work as the Marketing Manager for Amgen GmbH in Munich, Germany, where he was in charge of the launch of Aranesp® (Erythropoietin; darbepoetin alfa).
Prior to joining Quanta, Peter established and managed the DJO/Aircast regional offices in Hong Kong. Peter has a clinical background and holds an MBA in Strategic Marketing from the University of Hull as well as an EMBA in International Marketing from the KS Graduate Business School St. Gallen, Switzerland.
Chief Technology Officer
Clive was part of the founding team that initially developed the concept of Quanta’s SC+ system and obtained initial venture funding.
Previously, Clive worked for the BMW group with responsibility for the vehicle physics department. In 2001, he became an honorary professor within the Department of Engineering and Physics at Heriot-Watt University and in 2011 was elected a Fellow of the Royal Academy of Engineering and a Fellow of the Institute of Physics. Most recently, in 2018, Clive was accepted as a committee member of the IEC standards setting body for dialysis systems (60601-2-16).
Chief of Operations
Rolf has 25 years of experience in purchasing, supply chain and operations within the pharmaceuticals and medical device industries. Before joining Quanta, Rolf held the position of Director Supply Chain, Outsourced Manufacturing and Facility Management at Biocartis, where he was responsible for the outsourced manufacturing activities and led the selection and contracting process for outsourcing and implementation of supply chain and logistics processes to support product launch. Previously, Rolf has held various senior leadership roles with Merck Animal Health, Intervet Schering Plough Animal Health and Intervet International. Rolf has a Bachelors Degree in Economics from the University of Applied Sciences in Arnhem, Netherlands.
Director of QARA
Dr Chanel Allen-Megahey graduated from Queens University Belfast with a PhD in Molecular Microbiology. After university, her first job was as manager of QARA in HeartSine Technologies where she steered the Company to successful CE marking and FDA clearance for its innovative Class III heart defibrillator and accessory product range. Subsequently, Chanel worked for TriVirix, a CMO organisation that supplied electromechanical equipment for medical device companies.
There followed a series of Quality and Compliance roles in aerospace companies (RFD Beaufort, Survitec and Thompson) supporting multi-site global supply and servicing of safety and survival equipment, including the creation and operation of a Quality Management System and manufacturing facility for an aircraft seat manufacturer start-up. Chanel then worked as a Regulatory Affairs Manager for TG Eakin, with responsibility for FDA regulatory compliance for Class I-III multi-site device manufacturing. Prior to joining Quanta, her most recent role has been as FDA regulatory compliance consultant in support of a start-up company in the realignment of their electronics and software development process.
Amit is a technical leader with a strong background in complex systems engineering, having successfully launched multiple mission-critical systems for medical devices, life sciences and other applications. He has a passion for innovation and a proven track-record of building, motivating and energising product development teams. Amit joined Quanta in 2016 from a position of Head of Engineering at Biocartis, where he helped launch their flagship product in molecular diagnostics and was part of the leadership team that took the company to IPO. He has also previously held various engineering leadership roles at Life Technologies, Luminous Medical and Covidien. Amit has a Masters in Biomedical Engineering from the University of Minnesota, Twin Cities, USA and a Bachelor’s in Electrical Engineering from Sivaji University in India.
Chief Medical Officer
Dr Paul Komenda, Associate Professor of Medicine at the University of Manitoba, is a fellow of the American Society of Nephrology and the Royal College of Physicians and Surgeons Canada and has extensive clinical and academic experience. Dr Komenda previously served on the Scientific Advisory Board of NxStage Medical. He gained his medical qualification in 2001 from the University of Manitoba and is a board certified Nephrologist. Dr Komenda studied health economics and holds a Masters in Health Administration from the University of British Columbia and is also the Medical Director of a large Home Haemodialysis Program at the Seven Oaks General Hospital in Manitoba.
Dr Komenda has over 130 published peer reviewed articles in health services research and clinical nephrology and, with a specialist knowledge and interest in the field of home dialysis and health economics, Dr. Komenda is highly regarded as an expert in his field.